<DOC>
	<DOCNO>NCT02974868</DOCNO>
	<brief_summary>Study B7931005 investigate JAK3 inhibitor PF- 06651600 TYK2/JAK1 inhibitor PF-06700841 Alopecia Areata . This Phase 2a , randomize , double blind , parallel group , multicenter study enroll total approximately 132 subject ( expect provide approximately 90 completers ) . The study conduct approximately 30 40 site .</brief_summary>
	<brief_title>Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata</brief_title>
	<detailed_description />
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<criteria>Male female subject 18 75 year age , inclusive , time informed consent . Must moderate severe alopecia areata : History human immunodeficiency virus ( HIV ) positive HIV serology screening , Infected hepatitis B hepatitis C virus . Have evidence active latent inadequately treated infection Mycobacterium tuberculosis ( TB ) Have receive following treatment regiment specify timeframes outline : Within 6 month first dose study drug : Any cell deplete agent Within 12 week first dose study drug : Any study JAK inhibitor ; Other biologics Within 8 week first dose study drug : Participation study involve investigational drug ( ) Within 6 week first dose study drug : Have vaccinate live attenuate live vaccine . Within 4 week first dose study drug : Use oral immune suppressant ; Phototherapy ( NB UVB ) broad band phototherapy ; Regular use ( 2 visit per week ) tan booth/parlor . Within 2 week first dose study drug : Topical treatment could affect AA ; Herbal medication unknown property know beneficial effect AA .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Phase 2</keyword>
	<keyword>randomize</keyword>
	<keyword>double-blind</keyword>
	<keyword>placebo</keyword>
	<keyword>alopecia areata</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>JAK</keyword>
	<keyword>janus kinase</keyword>
	<keyword>moderate</keyword>
	<keyword>severe</keyword>
</DOC>